Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus

Ophthalmologica

Volumn 234, Issue 1, 2015, Pages 6-25

  Berger, Alan R ^a   Cruess, Alan F ^b   Altomare, Filiberto ^a   Chaudhary, Varun ^c   Colleaux, Kevin ^d   Greve, Mark ^e   Kherani, Amin ^f   Mandelcorn, Efrem D ^a   Parsons, Hugh ^g   Rheaúme, Marc André ^h   Tourville, Eric ⁱ  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITÉ LAVAL   (Canada)

Author keywords

Algorithms; Canadian expert consensus; Laser; Neovascularization; Retina; Retinal vein occlusion; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR;

ALGORITHM; ARTICLE; BRANCH RETINA VEIN OCCLUSION; CANADA; CENTRAL RETINA VEIN OCCLUSION; CHORIORETINAL VENOUS ANASTOMOSIS; CLINICAL FEATURE; COMPLICATION; CONSENSUS; DRUG IMPLANT; ECONOMIC ASPECT; HEALTH CARE NEED; HUMAN; LOW LEVEL LASER THERAPY; MEDICAL SPECIALIST; MORTALITY; PATHOGENESIS; PRACTICE GUIDELINE; QUALITY OF LIFE; RETINA VEIN OCCLUSION; STEROID THERAPY; VEIN ANASTOMOSIS; VITRECTOMY; LASER COAGULATION; PATHOPHYSIOLOGY; PROCEDURES; RETINAL VEIN OCCLUSION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; CANADA; CONSENSUS; HUMANS; LASER COAGULATION; RETINAL VEIN OCCLUSION; VISUAL ACUITY;

EID: 84942295445     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000381357     Document Type: Article

References (117)

1. Rogers SL, McIntosh RL, Lim L, et al: Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117: 1094-1101.
2. Cugati S, Wang JJ, Rochtchina E, Mitchell P: Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006; 124: 726-732.
3. Klein R, Moss SE, Meuer SM, Klein BE: The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126: 513-518.
4. Rogers S, McIntosh RL, Cheung N, et al: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-319.
5. Jaulim A, Ahmed B, Khanam T, Chatziralli IP: Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013; 33: 901-910.
6. London NJ, Brown G: Update and review of central retinal vein occlusion. Curr Opin Ophthalmol 2011; 22: 159-165.
7. Rehak J, Rehak M: Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111-131.
8. Fraenkl SA, Mozaffarieh M, Flammer J: Retinal vein occlusions: the potential impact of a dysregulation of the retinal veins. EPMA J 2010; 1: 253-261.
9. Yoshimura T, Sonoda KH, Sugahara M, et al: Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009; 4:e8158.
10. Noma H, Funatsu H, Yamasaki M, et al: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140: 256-261.
11. Noma H, Funatsu H, Yamasaki M, et al: Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion. Eye 2008; 22: 42-48.
12. Noma H, Funatsu H, Mimura T, Harino S, Sone T, Hori S: Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular edema and central retinal vein occlusion. Acta Ophthalmol 2010; 88: 646-651.
13. Noma H, Funatsu H, Mimura T, Harino S, Hori S: Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009; 116: 87-93.
14. Boyd SR, Zachary I, Chakravarthy U, et al: Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002; 120: 1644-1650.
15. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG: Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 2013; 120: 795-802.
16. Cunha-Vaz J: Retinal vein occlusion. Ophthalmologica 2011; 226: 3.
17. David R, Zangwill L, Badarna M, Yassur Y: Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197: 69-74.
18. Hayreh SS, Zimmerman MB, Podhajsky P: Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117: 429-441.
19. Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 1986; 104: 34-41.
20. Cheung N, Klein R, Wang JJ, et al: Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008; 49: 4297-4302.
21. Sofi F, Marcucci R, Fedi S, et al: High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion. Atherosclerosis 2010; 210: 278-281.
22. Di Capua M, Coppola A, Albisinni R, et al: Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2010; 30: 16-22.
23. Turello M, Pasca S, Daminato R, et al: Retinal vein occlusion: evaluation of 'classic' and 'emerging' risk factors and treatment. J Thromb Thrombolysis 2010; 29: 459-464.
24. O'Mahoney PR, Wong DT, Ray JG: Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126: 692-699.
25. Werther W, Chu L, Holekamp N, Do DV, Rubio RG: Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol 2011; 129: 326-331.
26. Farahvash MS, Moradimogadam M, Farahvash MM, et al: Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. Arch Iran Med 2008; 11: 418-422.
27. Ageno W, Cattaneo R, Manfredi E, et al: Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res 2010; 125: 137-141.
28. Hayreh SS, Zimmerman MB, Podhajsky P: Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 180-196.
29. Rehak M, Krcova V, Slavik L, et al: The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol 2010; 45: 171-175.
30. Brown DM: New directions in RVO treatment. Retina Today 2010(suppl):3-7.
31. Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, et al; SCORE Study Investigator Group: SCORE Study Report 2: interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology 2009; 116: 756-761.
32. Hayreh SS, Zimmerman MB: Ocular neovascularization associated with central and hemicentral retinal vein occlusion. Retina 2012; 32: 1553-1565.
33. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102: 1434-1444.
34. Hayreh SS, Zimmerman MB: Hemicentral retinal vein occlusion: natural history of visual outcome. Retina 2012; 32: 68-76.
35. Hayreh S: Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retinal Eye Res 2005; 24: 493-519.
36. Hamid S, Mirza SA, Shokh I: Anatomic pattern of arteriovenous crossings in branch retinal vein occlusion. J Pak Med Assoc 2008; 58: 233-236.
37. Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF: Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983; 90: 488-506.
38. Hayreh SS, Zimmerman MB: Branch retinal vein occlusion: natural history of visual outcome. JAMA Ophthalmol 2014; 132: 13-22.
39. Ehlers JP, Fekrat S: Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011; 56: 281-299.
40. Kruger-Leite E, Jalkh AE, Avila MP, Trempe CL: Central visual field in patients with retinal branch vein occlusion. Ann Ophthalmol 1985; 17: 622-623.
41. Parodi MB, Bandello F: Branch retinal vein occlusion: classification and treatment. Ophthalmologica 2009; 223: 298-305.
42. Jonas J, Paques M, Monés J, Glacet-Bernard A: Retinal vein occlusions. Dev Ophthalmol 2010; 47: 111-135.
43. Jefferies P, Clemett R, Day T: An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions. Aust NZJ Ophthalmol 1993; 21: 213-217.
44. Hvarfner C, Andreasson S, Larsson J: Multifocal electroretinography and fluorescein angiography in retinal vein occlusion. Retina 2006; 26: 292-296.
45. Ota M, Tsujikawa A, Murakami T, et al: Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007; 91: 1644-1649.
46. Hayreh SS, Zimmerman MB, Podhajsky PA: Retinal vein occlusion and the optic disk. Retina 2012; 32: 2108-2118.
47. The Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
48. Hayreh SS, Podhajsky PA, Zimmerman MB: Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011; 118: 119-133.
49. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-282.
50. Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S: Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003; 121: 1297-1302.
51. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S: Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol 2010; 94: 319-323.
52. Cugati S, Wang JJ, Knudtson MD, et al: Retinal vein occlusion and vascular mortality pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114: 520-524.
53. Fekrat S, Shea AM, Hammill BG, et al: Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin 2010; 26: 223-230.
54. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A: Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012; 119: 1184-1189.
55. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A: Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012; 119: 2587-2591.
56. Ramezani A, Esfandiari H, Entezari M, et al: Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recentonset branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2012; 259: 1149-1160.
57. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND: Bevacizumab compared with macular laser grid photocoagulation for cystoids macular edema in branch retinal vein occlusion. Retina 2009; 29: 511-515.
58. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112.
59. Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133.
60. Campochiaro PA, Brown DM, Awh CC, et al: Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049.
61. Brown DM, Campochiaro PA, Bhisitkul RB, et al: Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602.
62. Heier JS, Campochiaro PA, Yau L, et al: Ranibizumab for macular edema due to retinal vein occlusion: Long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119: 802-809.
63. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG: Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 2013; 120: 1057-1063.
64. Varma R, Bressler NM, Suñer I, et al; BRAVO and CRUISE Study Groups: Improved visionrelated function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 2012; 119: 2108-2118.
65. Suñer IJ, Bressler NM, Varma R, et al: Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmol 2013; 131: 851-856.
66. Gerding H, Boscia F, Mones JM, et al: Ranibizumab ± adjunctive laser vs laser in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO): Design and baseline characteristics of the BRIGHTER study (abstract 607-B0134). ARVO Annu Meet, Orlando, May 2014.
67. Tadayoni R, Boscia F, Gerding H, et al: BRIGHTER: Ranibizumab with or without adjunctive laser vs laser alone in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) (abstract FP-FR-20). World Ophthalmol Congr, Tokyo, April 2014.
68. Boscia F, Gerding H, Pearce IA, et al: Efficacy and safety of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion: Design and baseline characteristics of the CRYSTAL study (abstract 606-B0133). ARVO Annu Meet, Orlando, May 2014.
69. Boyer D, Heier J, Brown DM, et al: Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012; 119: 1024-1032.
70. Holz FG, Roider J, Ogura Y, et al: VEGF trapeye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013; 97: 278-284.
71. Korobelnik JF, Holz FG, Roider J, et al: Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014; 121: 202-208.
72. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ: Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155: 429-437.
73. Boyer DS: Efficacy and Safety of Intravitreal Aflibercept Injection (IAI) for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO): 24-Week Results of the VIBRANT Study (abstract 604-B0131). ARVO Annu Meet, Orlando, May 2014.
74. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 1425-1433.
75. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC: Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57: 1026-1033.
76. Wang K, Wang Y, Gao L, Li X, Li M, Guo J: Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008; 31: 1541-1546.
77. Lee HB, Pulido JS, McCannel CA, Buettner H: Role of inflammation in retinal vein occlusion. Can J Ophthalmol 2007; 42: 131-133.
78. Jeanneteau F, Garabedian MJ, Chao MV: Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci USA 2008; 105: 4862-4867.
79. Ip MS, Scott IU, VanVeldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-1114.
80. Scott IU, Ip MS, VanVeldhuisen PC, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128.
81. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449.
82. Ding X, Li J, Hu X, Yu S, Pan J, Tang S: Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 2011; 31: 838-845.
83. Lim JW, Na KI: A comparative study between intravitreal triamcinolone and bevacizumab for macular edema due to central retinal vein occlusion with poor vision. Indian J Ophthalmol 2011; 59: 93-96.
84. Demir M, Dirim B, Acar Z, Sendul Y, Oba E: Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion. Indian J Ophthalmol 2013; 62: 279-283.
85. Tao Y, Hou J, Jiang YR, Li XX, Jonas JB: Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond) 2010; 24: 810-815.
86. Allergan Inc: Ozurdex ® Product Monograph, 2012.
87. Haller JA, Bandello F, Belfort R Jr, et al: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.
88. Capone A Jr, Singer MA, Dodwell DG, et al: Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta Study). Retina 2014; 34: 342-351.
89. Bezatis A, Spital G, Höhn F, et al: Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-the SOLO study. Acta Ophthalmol 2013; 91:e340-e347.
90. Matonti F, Meyer F, Guigou S, et al: Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol 2013; 91:e584-e586.
91. Boyer DS, Yoon YH, Belfort R Jr, et al: Threeyear, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914.
92. Azad R, Vivek K, Sharma Y, Chandra P, Sain S, Venkataraman A: Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion. Indian J Ophthalmol 2012; 60: 263-266.
93. Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C: Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 2012; 22: 607-614.
94. Buddi R, Eliott D: Evaluation and management of retinal vein occlusion. Rev Ophthalmol, http://www.revophth.com/content/d/wills-eye-resident-case-series/d/1213/p/22849/c/25432 (accessed July 27, 2014).
95. McAllister IL, Gillies ME, Smithies LA, et al: The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology 2010; 117: 954-965.
96. Opremcak EM, Bruce RA: Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999; 19: 1-5.
97. Mason J 3rd, Feist R, White M Jr, Swanner J, McGwin G Jr, Emond T: Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology 2004; 111: 540-545.
98. Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE: Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006; 26: 297-305.
99. Liang XL, Chen HY, Huang YS, et al: Pars plana vitrectomy and internal limiting membrane peeling for macular oedema secondary to retinal vein occlusion: a pilot study. Ann Acad Med Singapore 2007; 36: 293-297.
100. Furino C, Ferrari TM, Boscia F, et al: Combined radial optic neurotomy, internal limiting membrane peeling, and intravitreal triamcinolone acetonide for central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 422-425.
101. Mandelcorn MS, Nrusimhadevara RK: Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina 2004; 24: 348-355.
102. Mandelcorn MS, Mandelcorn E, Guan K, et al: Surgical macular decompression for macular edema in retinal vein occlusion. Can J Ophthalmol 2007; 42: 116-122.
103. Radetzky S, Walter P, Fauser S, Koizumi K, Kirchhof B, Joussen AM: Visual outcome of patients with macular edema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane. Graefes Arch Clin Exp Ophthalmol 2004; 242: 273-278.
104. Hvarfner C, Larsson J: Vitrectomy for nonischaemic macular oedema in retinal vein occlusion. Acta Ophthalmol Scand 2006; 84: 812-814.
105. Pournaras CJ, Petropoulos IK, Pournaras JA, et al: The rationale of retinal endovascular fibrinolysis in the treatment of retinal vein occlusion: from experimental data to clinical application. Retina 2012; 32: 1566-1573.
106. Yamamoto T, Kamei M, Sakaguchi H, et al: Comparison of surgical treatments for central retinal vein occlusion; RON vs. cannulation of tissue plasminogen activator into the retinal vein. Retina 2009; 29: 1167-1174.
107. Hattenbach LO, Friedrich Arndt C, Lerche R, et al: Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009; 29: 932-940.
108. Kadonosono K, Yamane S, Arakawa A, et al: Endovascular cannulation with a microneedle for central retinal vein occlusion. JAMA Ophthalmol 2013; 131: 783-786.
109. Pinna A, Simula P, Zinellu A: Subcutaneous nadroparin calcium in the treatment of recent onset retinal vein occlusion: a pilot study. J Ocul Pharmacol Ther 2012; 28: 448-454.
110. Maeno T, Tano R, Takenaka H, Mano T: Edaravone (MCI-186) is effective as a free radical scavenger following arteriovenous sheathotomy for treatment of macular oedema associated with branch retinal vein occlusion. Br J Ophthalmol 2009; 93: 1479-1482.
111. Glacet-Bernard A, Atassi M, Fardeau C, et al: Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol 2011; 249: 505-512.
112. Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K: Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol 2011; 95: 788-792.
113. Sun C, Li XX, He XJ, Zhang Q, Tao Y: Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion. Exp Eye Res 2013; 113: 105-116.
114. Murakami T, Takagi H, Kita M, et al: Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006; 142: 318-320.
115. Sakuma T, Mizota A, Inoue J, Tanaka M: Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2010; 150: 876-882.
116. Tagami M, Kusuhara S, Imai H, Honda S, Tsukahara Y, Negi A: Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion. Ophthalmologica 2011; 226: 81-86.
117. Murakami T, Takagi H, Ohashi H, et al: Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina 2007; 27: 1031-1037.